DPRP2 Inhibitors
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Vildagliptin | 274901-16-5 | sc-208485 | 10 mg | $176.00 | 4 | |
Vildagliptin acts as a selective inhibitor of DPP-4, showcasing unique molecular interactions that stabilize the enzyme-substrate complex. Its structure allows for specific binding, leading to altered reaction kinetics characterized by a notable decrease in enzymatic activity. The compound's ability to modulate the conformational dynamics of DPP-4 enhances its inhibitory effects, making it a subject of interest in studying enzyme regulation and metabolic pathways. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This DNA methyltransferase inhibitor promotes demethylation, which could potentially downregulate DPRP2 expression by altering the methylation status of its gene promoter, leading to transcriptional silencing. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
As a histone deacetylase inhibitor, Trichostatin A can cause an increase in histone acetylation that may lead to a more open chromatin structure around the DPRP2 gene, potentially resulting in decreased transcriptional activity. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
By binding to DNA, Actinomycin D inhibits the progression of RNA polymerase, which can result in decreased transcription of the DPRP2 gene, thereby reducing its mRNA and protein levels. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide inhibits eukaryotic protein synthesis by preventing ribosomal translocation, leading to a decrease in the synthesis of proteins, including the potential reduction of DPRP2 levels. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
This mTOR inhibitor can lead to the attenuation of cap-dependent translation, which may result in reduced synthesis of proteins encoded by genes like DPRP2, leading to lower protein levels. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
This compound selectively inhibits MEK, which, as part of the MAP kinase pathway, may lead to decreased expression of downstream genes such as DPRP2 by altering transcription factor activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that can cause an accumulation of ubiquitinated proteins, potentially leading to altered cellular signaling and a consequent decrease in DPRP2 protein levels due to shifts in gene expression priorities. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB 431542 inhibits the TGF-β receptor ALK5, which may lead to downregulation of downstream target genes, including the potential for reduced transcription of the DPRP2 gene. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
This PI3K inhibitor can lead to the inhibition of the AKT signaling pathway, potentially resulting in decreased levels of DPRP2 mRNA synthesis as part of the broader effects on cellular growth and survival pathways. | ||||||